Multiple Myeloma Hub

How can ocular toxicities associated with belantamab mafodotin be effectively monitored and managed in clinical practice? Learn more: bit.ly/4xR4JZ8 #MultipleMyeloma #myeloma #mmsm #MedEd @MilesPrince4 @DrRakeshPopat @heinzludwig4

CRS and ICANS are key safety considerations for BsAb therapy in relapsed/refractory #MultipleMyeloma. We summarize the #IMWG consensus recommendations, which provide a practical guide to the early recognition, grading, and management of these adverse events. Explore the full visual abstract here: multiplemyelomahub.com/medical-inform… #myeloma #mmsm #MedEd #Immunotherapy

MM in the Know is our social-media-based patient education program, providing accessible, evidence-based information for people living with multiple myeloma and those who care for them. Our latest educational resource explains what bispecific antibodies are and how they work in multiple myeloma. If you care for patients with multiple myeloma, please consider sharing this post and the MM in the Know social channels with patients, caregivers, and anyone who may benefit. #MultipleMyeloma #myeloma #mmsm #MedEd #PatientEducation

New publication 📝 Phase III MajesTEC-9 results, presented at #EHA2026, showed teclistamab monotherapy improved PFS vs PVd/Kd in patients with relapsed/refractory #MultipleMyeloma after 1–3 prior LoT (median PFS, NR vs 8.2 months; HR, 0.29; 95% CI, 0.23–0.38; p < 0.0001). Learn more about EHA2026: bit.ly/4vC6YOf #myeloma #mmsm #MedNews #MedEd

The Multiple Myeloma Hub spoke with Binod Dhakal about the latest findings from the phase I CaMMouflage trial evaluating CB-011 in patients with RRMM, presented at #EHA2026. Watch the full video here: bit.ly/3QYtnX0 #mmsm #myeloma #MedEd #MedNews #MedicalCongress @bhemato

In our latest podcast, Miles Prince and members of the Multiple Myeloma Hub Steering Committee discuss practical considerations for integrating BCMA-directed bispecific antibodies into the treatment paradigm for multiple myeloma, including patient selection, treatment sequencing, and community-based care. Listen here: shows.acast.com/5ebe8cc563e3d8… #MultipleMyeloma #myeloma #mmsm #MedEd @MilesPrince4

The Multiple Myeloma Hub spoke with Meral Beksaç at #EHA2026 about key findings from two DREAMM-8 subgroup analyses evaluating outcomes in patients with only 1 prior LOT and those with sustained MRD negativity. bit.ly/3SBR08l #mmsm #myeloma #MedEd #MedNews #MedicalCongress @mbeksac56

Binod Dhakal discusses the latest findings from the phase I CaMMouflage trial evaluating CB-011 in patients with RRMM, presented at #EHA2026. shows.acast.com/mm-hub #mmsm #myeloma #MedEd #MedNews #MedicalCongress @bhemato

Transitioning BCMA-directed bispecific antibodies into community practice has the potential to improve access and convenience, but requires appropriate infrastructure, training, and multidisciplinary coordination. Watch the full video here: bit.ly/3ReIwUd #MultipleMyeloma #mmsm #myeloma #MedEd @MilesPrince4

The Multiple Myeloma Hub spoke with Binod Dhakal at #EHA2026 about the latest findings from the phase I CaMMouflage trial evaluating CB-011 in patients with RRMM. Watch here: bit.ly/3QYtnX0 #mmsm #myeloma #MedEd #MedNews #MedicalCongress @bhemato This educational resource is independently supported by Caribou Biosciences. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.

New publication 📝 SUCCESSOR-2 phase III results, presented at #EHA2026, show MeziKd improved PFS vs Kd in Len- and anti-CD38 mAb-exposed relapsed/refractory #MultipleMyeloma (18.0 vs 8.3 months; HR, 0.48; 95% CI, 0.36–0.63; p < 0.0001). Learn more about EHA 2026: bit.ly/4vC6YOf #myeloma #mmsm #MedNews #MedEd

In our latest podcast, Lisa Leypoldt and members of the Multiple Myeloma Hub Steering Committee discuss practical strategies for managing belantamab mafodotin-associated ocular toxicities in multiple myeloma, including the role of dose modifications and extended dosing intervals in supporting treatment continuity. Listen here: shows.acast.com/5ebe8cc563e3d8… #MultipleMyeloma #myeloma #mmsm #MedEd

How can BCMA-directed bispecific antibodies be safely integrated into routine and community-based care for patients with #MultipleMyeloma? Learn more about patient selection, treatment sequencing, toxicity management, and community implementation: bit.ly/3ReIwUd #myeloma #mmsm #MedEd @MilesPrince4 @DrRakeshPopat @heinzludwig4

New publication 📝 Consensus recommendations from the Pan-Pacific Multiple Myeloma Working Group, published in Clinical Hematology International, outline 7 consensus statements on the use of MRD-adapted therapy in #MultipleMyeloma, including dynamic MRD monitoring to guide risk stratification and treatment decisions. Learn more about risk in MM: bit.ly/4xZmzZZ #myeloma #mmsm #MedNews #MedEd

Thank you to our funders, who make it possible for us to deliver the Multiple Myeloma Hub. - Bristol Myers Squibb - Caribou Biosciences - GSK - Johnson & Johnson Innovative Medicine - Legend Biotech - Pfizer - Roche #mmsm #MultipleMyeloma

Understanding how visual symptoms affect a patient's daily life is an important part of managing belantamab mafodotin-associated ocular toxicity. Watch the full video here: bit.ly/4xR4JZ8 #MultipleMyeloma #mmsm #myeloma #MedEd

Binod Dhakal discusses findings from the phase I CaMMouflage trial evaluating CB-011, an allogeneic anti-BCMA CAR T-cell therapy, in patients with RRMM at #EHA2026. Watch here: bit.ly/3QYtnX0 #mmsm #myeloma #MedEd #MedNews #MedicalCongress @bhemato This educational resource is independently supported by Caribou Biosciences. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.

Meral Beksaç discusses key findings from two subgroup analyses of the phase III DREAMM-8 trial in RRMM at #EHA2026. bit.ly/3SBR08l #mmsm #myeloma #MedEd #MedNews #MedicalCongress @mbeksac56 This educational resource is independently supported by GSK. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.

During our latest steering committee meeting, Miles Prince and the faculty discussed the evolving role of BCMA-directed bispecific antibodies in #MultipleMyeloma, including patient selection, treatment sequencing, toxicity management, and practical considerations for community-based care. multiplemyelomahub.com/medical-inform… #myeloma #mmsm #MedEd @MilesPrince4 @DrRakeshPopat @heinzludwig4

The Multiple Myeloma Hub spoke with Vania Tietsche de Moraes Hungria about the updated 4-year results from the phase III DREAMM-7 trial in RRMM presented at #EHA2026. bit.ly/4uMPQUR #mmsm #myeloma #MedEd #MedNews #MedicalCongress @dra_v_hungria

Vania Tietsche de Moraes Hungria discusses the updated 4-year results from the phase III DREAMM-7 trial in RRMM, presented at #EHA2026. bit.ly/4f4kbZp? #mmsm #myeloma #MedEd #MedNews #MedicalCongress @dra_v_hungria